The Cannabis sector that has been seen to trade on volatility in 2017, got a good boost with the regulatory update from the horse’s mouth, Federal Government’s Greg Hunt (Health Minister), as per which cannabinoid medicines manufactured by Australian companies will now be allowed to be exported. This sets the cannabis stocks to foray into untapped opportunity areas while catering to domestic supply-demand scenario. With this news, investors were found to be laying their hands on pot stocks that also got a pump up at the start of the new year owing to sector driven sentiments with the news of California legalizing marijuana coming-in for both medical and recreational use.

AusCann Group Holdings Ltd (AC8), which has full set of licenses to grow and manufacture cannabis medicines in Australia, soared over 53.6% on January 04, 2018.

Cann Group Ltd (CAN) was up over 35.4% to a high level, while The Hydroponics Company Ltd (THC) rallied up about 30.8% with more potential to grow on a speculative note.

On the similar note, Creso Pharma Ltd grew 20.6% and its exposure to Canadian market is gaining traction with Canada seeking to legalize cannabis soon. Stemcell United Ltd, which is yet to prove the potential in the sector, also got a 32.6% boost.

From a more speculative position that was seen last year, the sector seems to be transforming into the one with a healthy foothold, and so is the case with key cannabis stocks. The stocks will be worth a watch this year.

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.